Molecular Prognostic Factors for Breast Carcinoma

The Breast ◽  
2018 ◽  
pp. 258-263.e2
Author(s):  
Oluwadamilola M. Fayanju ◽  
Anthony Lucci
Keyword(s):  
Prognostic Factors ◽  
Breast Carcinoma

Correlation of Histologic Prognostic Factors in Core Biopsies and Therapeutic Excisions of Invasive Breast Carcinoma

2003 ◽  
Vol 27 (1) ◽  
pp. 11-15 ◽  
Author(s):  
Gavin C. Harris ◽  
Helen E. Denley ◽  
Sarah E. Pinder ◽  
Andrew H. S. Lee ◽  
Ian O. Ellis ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Breast Carcinoma ◽  
Invasive Breast Carcinoma

Correlation of the SUVmax of FDG-PET and ADC values of diffusion-weighted MR imaging with pathologic prognostic factors in breast carcinoma

2016 ◽  
Vol 85 (5) ◽  
pp. 943-949 ◽  
Author(s):  
Kazuhiro Kitajima ◽  
Toshiko Yamano ◽  
Kazuhito Fukushima ◽  
Yasuo Miyoshi ◽  
Seiichi Hirota ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Breast Carcinoma ◽  
Mr Imaging ◽  
Fdg Pet ◽  
Diffusion Weighted ◽  
Adc Values

scholarly journals Correlation of primary tumor size and axillary nodal status with tumor suppressor gene p53 in breast carcinoma

2002 ◽  
Vol 59 (1) ◽  
pp. 29-32 ◽  
Author(s):  
Brano Topic ◽  
Nebojsa Stankovic ◽  
Dragutin Savjak ◽  
Slavko Grbic
Keyword(s):  
Prognostic Factors ◽  
Breast Carcinoma ◽  
Tumor Suppressor ◽  
Tumor Suppressor Gene ◽  
Tumor Size ◽  
Primary Tumor ◽  
Suppressor Gene ◽  
Nodal Status ◽  
Primary Tumor Size ◽  
Tumor Suppressor Gene P53

Correlation of standard path morphological prognostic parameters, primary tumor size and axillary nodal status with new prognostic factor in breast carcinoma: tumor suppressor gene p53 was analyzed. The studied sample included 65 women who underwent surgery for breast carcinoma at the Surgical Clinic of Clinical Center Banja Luka, from January 1st 1997 till January 1st 1999. Statistical data analysis was performed and correlation of prognostic factors was determined. The majority of authors in this field agree that the primary tumor size and axillary nodal status are the two most important prognostic factors. These factors are the best predictors of prognosis and survival of women who had the tumor and were operated on. Tumor markers were immunohistochemically determined in the last ten years and, according to the majority of authors, are still considered the additional or relative prognostic factors in breast carcinoma. Their prognostic value and significance increase almost daily. Most frequently determined tumor markers are bcl-2, pS2, Ki-67 and p53. There was a positive, directly proportional relationship between primary tumor size and tumor suppressor gene p53, but there was no positive correlation between the axillary nodal status and tumor suppressor gene p53. Significance of determination of new tumor markers as the prognostic factors was emphasized. These markers represent a powerful tool in the early detection and prevention of breast carcinoma.

scholarly journals Correlation of her 2/neu gene amplification with immunohistochemistry and other prognostic factors in breast carcinoma

2011 ◽  
Vol 27 (3) ◽  
pp. 196
Author(s):  
Saime Sezgin Ramadan ◽  
Ozlem Yapicier ◽  
Selcuk Kihtir ◽  
Ayhan Erdemir ◽  
Tugser Hakan Dogan ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Breast Carcinoma ◽  
Gene Amplification ◽  
Her 2

A CROSS SECTIONAL STUDY OF BREAST CANCER HISTOMORPHOLOGY AND ITS CORRELATION WITH ER/PR, HER 2NEU AND KI-67 EXPRESSION IN A TERTIARY CARE HOSPITAL AT KANPUR

2021 ◽  
pp. 9-12
Author(s):  
Mahendra Singh ◽  
Shobha Dwivedi ◽  
Yukteshwar Mishra ◽  
Sakshi Tripathi
Keyword(s):  
Prognostic Factors ◽  
Breast Carcinoma ◽  
Tertiary Care ◽  
Radical Mastectomy ◽  
Cross Sectional Study ◽  
Low Grade ◽  
Care Hospital ◽  
Sectional Study ◽  
Ki 67 ◽  
Cross Sectional

BACKGROUND Breast carcinoma is the most well-known malignancy in women. Different predictive and prognostic factors, for example, estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor (Her2neu), and Ki67 could inuence breast carcinoma behaviour, yet to date no authoritative connection has been set up among them and breast carcinoma subtypes. In this way present study was done to determine the interrelationships of these predictive and prognostic factors for breast carcinoma. METHODS In this cross sectional study, a total of 50 lumpectomy, modied radical mastectomy specimens of diagnosed carcinoma breast were included in this study. The histopathological grading of the breast carcinoma was performed by Nottingham modication of the Bloom Richardson grading system. All the cases went through immunohistochemistry for ER, PR, Her2neu and Ki67 expression. Association of ER, PR, Her2neu and Ki67 with different histomorphology was established. RESULTS The ER positivity was signicantly lower in tumors >5 cm size whereas Ki67was signicantly increased with increased tumor size. The ER positivity was signicantly lower in high grade tumors as compared to low grade tumors. The positive ER, PR, Her2neu and Ki67 were comparable in between premenopausal and post-menopausal age groups CONCLUSION The present study concludes that ER, PR show inverse while ki67 showed a direct relationship with the tumor grade. Correlation of histomorphology of breast tumor and Her2neu status could not be established.

Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years.

1989 ◽  
Vol 7 (9) ◽  
pp. 1239-1251 ◽  
Author(s):  
P P Rosen ◽  
S Groshen ◽  
P E Saigo ◽  
D W Kinne ◽  
S Hellman
Keyword(s):  
Prognostic Factors ◽  
Breast Carcinoma ◽  
Local Recurrence ◽  
Median Survival ◽  
Tumor Size ◽  
Stage I ◽  
Axillary Lymph ◽  
Axillary Lymph Node Metastases ◽  
Systemic Recurrence

Prognostic factors have been examined in 644 patients with tumor-node-metastasis (TNM) stage T1 breast carcinoma treated by mastectomy and followed for a median of 18.2 years. Overall, 148 patients (23%) died of recurrent breast carcinoma. Eighteen (3%) were alive with recurrent disease and 478 (74%) were alive or died of other causes without recurrence. Unfavorable clinicopathologic features were larger tumor size (1.1 to 2.0 cm v less than or equal to 1 cm), perimenopausal menstrual status, the number of axillary lymph node metastases, poorly differentiated grade, presence of lymphatic tumor emboli (LI) in breast tissue near the primary tumor, blood vessel invasion (BVI), and an intense lymphoplasmacytic reaction around the tumor. Median survival after recurrence for the entire series was 2 years. This was not significantly influenced by tumor size, the number of axillary nodal metastases, the type of treatment for recurrence, or the interval to recurrence. The proportions surviving 5 and 10 years after recurrence were 17% and 5%, respectively. Among T1N0M0 cases, the chance of a local recurrence was 2.8% within 20 years. Median survival of T1N0M0 cases after local recurrence (4.5 years) was significantly longer than after systemic recurrence (1.5 years). A similar trend (3.7 v 2.0 years), not statistically significant, was seen in T1N1M0 patients, who had a 6.5% chance of local recurrence within 20 years. Median survival following systemic recurrence detected 10 or more years after diagnosis in T1N0M0 and in T1N1M0 patients was significantly longer than the median survival for systemic recurrences found in the first decade of follow-up. This difference did not apply following local recurrence in either T1N0M0 or T1N1M0 cases. It is evident that patients with T1 breast carcinoma can be subdivided into differing prognostic groups and this must be taken into account when considering the role of adjuvant chemotherapy for stage I disease. Systemic adjuvant treatment may prove to be beneficial for patients with unfavorable prognostic factors, while women with an especially low risk for recurrence (eg, T1N0M0 tumor 1.0 cm or less) might be spared such treatment.

Sign in / Sign up

Export Citation Format

Share Document